Pfizer Inc. (NYSE:PFE) Shares Acquired by Waldron Private Wealth LLC

Waldron Private Wealth LLC lifted its holdings in Pfizer Inc. (NYSE:PFE) by 5.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,399 shares of the biopharmaceutical company’s stock after acquiring an additional 3,059 shares during the period. Waldron Private Wealth LLC’s holdings in Pfizer were worth $1,806,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in PFE. Olistico Wealth LLC acquired a new position in Pfizer during the 2nd quarter worth $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer in the 2nd quarter valued at about $29,000. Quarry LP bought a new stake in shares of Pfizer during the 2nd quarter worth about $31,000. Trivant Custom Portfolio Group LLC raised its position in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. acquired a new position in shares of Pfizer in the 2nd quarter worth approximately $34,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

NYSE PFE traded down $0.08 during trading on Tuesday, hitting $28.85. 18,735,277 shares of the company’s stock were exchanged, compared to its average volume of 36,949,816. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The company has a market cap of $163.48 billion, a PE ratio of -479.33, a P/E/G ratio of 1.02 and a beta of 0.67. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54. The stock’s 50 day moving average price is $29.07 and its two-hundred day moving average price is $28.47.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter last year, the company earned $0.67 earnings per share. The company’s revenue was up 2.1% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 5.82%. Pfizer’s dividend payout ratio is presently -2,800.00%.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. UBS Group upped their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Thursday, October 3rd. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.91.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.